Office of Research, UC Riverside
Search Funding

Program TitlePAR-22-242: Bioengineering Research Grants (BRG)
Program WebsiteLink
AgencyNIH
Internal UCR Deadline4/5/2023
Agency Final Deadline6/5/2023
Program Deadline(s)10/5/2023   2/5/2024   6/6/2024   



Purpose of this funding opportunity announcement is to encourage
collaborations- between life science and physical science- that: 1)
apply a multidisciplinary bioengineering approach to solve biomedical
problems; and 2) develop, integrate, optimize, validate, translate or
accelerate adoption of promising tools, methods and techniques: a) that
fulfill an unmet need and address specific research or clinical problem
in basic, translational, and/or clinical science and practice, b)
capable of enhancing our understanding of health and disease, and/or c)
improve practice of medicine. Applications may propose design-directed,
developmental, discovery-driven, or hypothesis-driven research, and this
FOA is appropriate for small teams applying an integrative approach to
increase our understanding of and solve problems in biological, clinical
or translational science.


Award budgets: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award project period: The scope of the proposed project should determine the project
period. The maximum award period is 5 years depending on the policy of
each NIH Institute. Applicants are encouraged to review the current
funding policy of each NIH Institute.

Number of applications: Applicant
organizations may submit more than one application, provided that each
application is scientifically distinct. (The NIH will not accept
duplicate or highly overlapping applications under review at the same
time.)

Examples of technologies that are of interest to NCI include, but are not limited to:



  • That assess the fit-for-purpose of biospecimens:
    determine the effects of collection, handling, processing, and storage
    on molecular and cellular components of interest;
  • For quantitative and qualitative measurement of
    molecular and cellular markers of cancer risk, causation, and risk
    modification- specifically the technologies that address preanalytic
    factors and optimized to work with non-invasive, minimally invasive or
    archived samples collected from multiple populations to enable high
    throughput analysis at scale;
  • For automated sample preparation for -omic analysis, and advanced multiplex and biosensor technologies for multiomic analysis
  • Portable non-sequencing based multiplex genotyping assays;
  • That measure cancer-relevant exposures, and
    molecular and cellular markers of exposures including human and
    microbial metabolites associated with cancer;
  • Computational and AI strategies intended for
    predicting cancer-relevant exposures or history of human exposures-
    based on host response including immune response, pathologies, molecular
    markers, and metabolites to inform basic and translational studies;
  • For advanced multiplex high-throughput
    technologies and biosensors for measuring natural anti-tumor immunity,
    immuno- genotyping and phenotyping
  • Blood immune cell and molecular profiling;
  • To monitor cancer treatment-related adverse events;
  • Wearable devices and biosensors to monitor lifestyle factors and cancer-relevant exposures;
  • At-home, high sensitivity and specific point-of-care or point-of-need cancer risk or prognostic tools;
  • Innovative tools intended for disseminating
    information such as risk, and cancer-related health outcomes to
    different population group;
  • Synthetic biology devices to advance understanding of cancer biology with a goal of improving cancer diagnosis and treatment;
  • Nanotechnologies capable of biological discovery;
  • Tools to enable deep tissue ex vivo and in vivo imaging and integration;
  • Next-generation non-invasive cancer molecular diagnostics platforms beyond tissue biopsies;
  • In vitro imaging diagnostic technologies;
  • Liquid biopsy technologies with the goal of improving cancer diagnosis and treatment;
  • Technologies for the detection and evaluation of cancer of unknown primary (CUP);
  • Technologies for neoantigen identification, including dendritic cell-displayed antigens and neoantigens; and
  • Engineered biomaterials that display, detect, or
    respond to physiologically-relevant properties of tumors or the tumor
    microenvironment.




Database Key: 2126966011